You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 277 No. 3, January 15, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Building a National Strategy for the Prevention and Management of and Research in Chronic Obstructive Pulmonary Disease

National Heart, Lung, and Blood Institute Workshop Summary

Thomas L. Petty, MD; Gail G. Weinmann, MD

JAMA. 1997;277(3):246-253.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CHRONIC obstructive pulmonary disease (COPD) is now the fourth leading cause of death in the United States, exceeded only by heart attacks, cancers, and stroke. It is estimated that in 1996 more than 100 000 people will die of COPD alone, though for many more COPD will be a contributing cause of death. The recently completed Lung Health Study, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) showed that sustained smoking cessation can be successful with coordinated intervention in up to 22% of subjects at risk of developing COPD.1 During the 5-year follow up period, smoking cessation resulted in a initial slight improvement then a slower rate of FEV1 decline compared with continued smokers. Since the rate of FEV1 decline is a powerful prognostic indicator, these results show not only the potential importance of early intervention, but also the . . . [Full Text PDF of this Article]


Author Affiliations

From the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.


Footnotes

The workshop was held in Bethesda, Md, on August 29-31,1995, and was sponsored by the Division of Lung Diseases, National Heart, Lung, and Blood Institute. A complete list of speakers appears at the end of this article.

Dr Petty is a member of the speakers bureaus of Boehringer Ingelheim, Glaxo, and 3M.

Reprints: Gail G. Weinmann, MD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, MSC 7952, Bethesda, MD 20892-7952.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.